Research ArticleOriginal Article
Open Access

Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan

Mazhar A. Khan, Sumaira Mehreen, Anila Basit, Raza A. Khan, Faheem Jan, Irfan Ullah, Muhammad Ihtesham, Afsar Khan, Ubaid Ullah and Arshad Javaid
Saudi Medical Journal December 2015, 36 (12) 1463-1471; DOI: https://doi.org/10.15537/smj.2015.12.12155

References

  1. ↵
    1. World Health Organization
    (2014) Global tuberculosis report (WHO, Geneva (CH)).
  2. ↵
    1. Gupta R,
    2. Cegielski JP,
    3. Espinal MA,
    4. Henkens M,
    5. Kim JY,
    6. Lambregts-Van Weezenbeek CS,
    7. et al.
    (2002) Increasing transparency in partnerships for health-introductiong the Green Light Committee. Trop Med Int Health 7:970–976.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Chan E,
    2. Iseman M
    (2008) Multidrug-resistant and extensively drug-resistant tuberculosis. A review. Curr Opin Infect Dis 21:587–595.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Kimerling ME,
    2. Kluge H,
    3. Vezhnina N,
    4. Iacovazzi T,
    5. Demeulenaere T,
    6. Portaels F,
    7. et al.
    (1999) Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 3:451–453.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Espinal MA,
    2. Kim SJ,
    3. Suarez PG,
    4. Kam KM,
    5. Khomenko AG,
    6. Migliori GB,
    7. et al.
    (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537–2545.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Javaid A,
    2. Hasan R,
    3. Zafar A,
    4. Ghafoor A,
    5. Pattan AJ,
    6. Rab A,
    7. et al.
    (2008) Prevalence of primary multidrug resistance to anti-tuberculosis drug in Pakistan. Int J Tuberc Lung Dis 12:326–331.
    OpenUrlPubMed
  7. ↵
    1. Yew WW,
    2. Chan CK,
    3. Chau CH,
    4. Tam CM,
    5. Leung CC,
    6. Wong PC,
    7. et al.
    (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744–751.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Tabarsi P,
    2. Chitsaz E,
    3. Tabatabaei V
    (2011) Revised category II regimen as an alternative strategy for retreatment of category I regimen failure and irregular treatment cases. Am J Ther 18:343–349.
    OpenUrlPubMed
  9. ↵
    1. Espinal MA
    (2003) Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 7:607–608.
    OpenUrlPubMed
  10. ↵
    1. Turett GS,
    2. Telzak EE,
    3. Torian LV,
    4. Alland D,
    5. Weisfuse I,
    6. Fazal BA
    (1995) Improved outcomes for patients with multi-drug-resistant tuberculosis. Clin Infect Dis 21:1238–1244.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Park SK,
    2. Kim CT,
    3. Song SD
    (1998) Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to Isoniazid and Rifampicin. Int J Tuberc Lung Dis 2:877–884.
    OpenUrlPubMedWeb of Science
  12. ↵
    1. World Health Organization
    (2010) The global plan to stop TB2011-2015: transforming the fight towards elimination of tuberculosis (World Health Organization, Geneva (CH)).
  13. ↵
    1. Shean KP,
    2. Willcox PA,
    3. Siwendu SN,
    4. Laserson KF,
    5. Gross L,
    6. Kammerer S,
    7. et al.
    (2008) Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa 1992-2002. Int J Tuberc Lung Dis 12:1182–1189.
    OpenUrlPubMedWeb of Science
  14. ↵
    1. Zhao M,
    2. Li X,
    3. Xu P,
    4. Shen X,
    5. Gui X,
    6. Wang L,
    7. et al.
    (2009) Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 4:e4370.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Telzak EE,
    2. Sepkowitz K,
    3. Alpert P,
    4. Mannheimer S,
    5. Medard F,
    6. El-Sadr W,
    7. et al.
    (1995) Multidrug-resistant tuberculosis in patient without HIV infection. N Engl J Med 333:907–911.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Park SK,
    2. Lee WC,
    3. Lee DH,
    4. Mitnick CD,
    5. Han L,
    6. Seung KJ
    (2004) Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 8:361–368.
    OpenUrlPubMedWeb of Science
  17. ↵
    1. Diel R,
    2. Nieman S
    (2003) Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001. Int J Tuberc Lung Dis 7:124–131.
    OpenUrlPubMedWeb of Science
  18. ↵
    1. Kim HR,
    2. Hwang SS,
    3. Kim HJ,
    4. Lee SM,
    5. Yoo CG,
    6. Kim YW,
    7. et al.
    (2007) Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45:1290–1295.
    OpenUrlCrossRefPubMedWeb of Science
    1. Chan ED,
    2. Laurel V,
    3. Strand MJ,
    4. Chan JF,
    5. Huynh ML,
    6. Goble M,
    7. et al.
    (2004) Treatment and outcome analysis of 205 patients with multi drug resistant tuberculosis. Am J Respir Crit Care Med 169:1103–1109.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Chiang CY,
    2. Enarson DA,
    3. Yu MC,
    4. Bai KJ,
    5. Huang RM,
    6. Hsu CJ,
    7. et al.
    (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 28:980–985.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Migliori GB,
    2. Besozzi G,
    3. Girardi E,
    4. Kliiman K,
    5. Lange C,
    6. Toungoussova OS,
    7. et al.
    (2007) Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30:623–626.
    OpenUrlAbstract/FREE Full Text
    1. Nathanson E,
    2. Lambregts-van Weezenbeek C,
    3. Rich ML,
    4. Gupta R,
    5. Bayona J,
    6. Blondal K,
    7. et al.
    (2006) Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 12:1389–1397.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Tahaoglu K,
    2. Torun T,
    3. Sevim T,
    4. Atac G,
    5. Kir A,
    6. Karasulu L,
    7. et al.
    (2001) The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345:170–174.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Nathanson E,
    2. Gupta R,
    3. Huamani P,
    4. Leimane V,
    5. Pasechnikov AD,
    6. Tupasi TE,
    7. et al.
    (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8:1382–1384.
    OpenUrlPubMedWeb of Science
  25. ↵
    1. Cox HS,
    2. Kalon S,
    3. Allamuratova S,
    4. Sizaire V,
    5. Tigay ZN,
    6. Rusch-Gerdes S,
    7. et al.
    (2007) Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: Treatment complexity and XDR-TB among treatment failures. PLoS ONE 2:e1126.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Dheda K,
    2. Shean K,
    3. Zumla A,
    4. Badri M,
    5. Streicher EM,
    6. Page-Shipp L,
    7. et al.
    (2010) Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 375:1798–1807.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Jeon CY,
    2. Hwang SH,
    3. Min JH,
    4. Prevots DR,
    5. Goldfeder LC,
    6. Lee H,
    7. et al.
    (2008) Extensively drug-resistant tuberculosis in South Korea: Risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 46:42–49.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. National Tuberculosis Institute, Bangalore
    (1974) Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 51:473–488.
    OpenUrlPubMedWeb of Science
  29. ↵
    1. Orenstein EW,
    2. Basu S,
    3. Shah NS,
    4. Andrews JR,
    5. Friedland GH,
    6. Moll AP,
    7. et al.
    (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9:153–161.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Johnston JC,
    2. Shahidi NC,
    3. Sadatsafavi M,
    4. Fitzgerald JM
    (2009) Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE 4:e6914.
    OpenUrlCrossRefPubMed
    1. Mitnick C,
    2. Bayona J,
    3. Palacios E,
    4. Shin S,
    5. Furin J,
    6. Alcantara F,
    7. et al.
    (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348:119–128.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Leimane V,
    2. Riekstina V,
    3. Holtz TH,
    4. Zarovska E,
    5. Skripconoka V,
    6. Thorpe LE,
    7. et al.
    (2005) Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365:318–326.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Shin SS,
    2. Pasechnikov AD,
    3. Gelmanova IY,
    4. Peremitin GG,
    5. Strelis AK,
    6. Andreev YG,
    7. et al.
    (2006) Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 10:402–408.
    OpenUrlPubMedWeb of Science
  34. ↵
    1. Kurbatova EV,
    2. Taylor A,
    3. Gammino VM,
    4. Bayona J,
    5. Becerra M,
    6. Danilovitz M,
    7. et al.
    (2012) Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis 92:397–403.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Rodriguez M,
    2. Monedero I,
    3. Caminero J,
    4. Encarnación M,
    5. Dominguez Y,
    6. Acosta I,
    7. et al.
    (2013) Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis 17:520–525.
    OpenUrl
  36. ↵
    1. Yew WW,
    2. Chan CK,
    3. Leung CC,
    4. Chau CH,
    5. Tam CM,
    6. Wong PC,
    7. et al.
    (2003) Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug- resistant tuberculosis: preliminary results of a retrospective study from Honk Kong. Chest 124:1476–1481.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Dye C,
    2. Williams BG
    (2000) Criteria for the control of drug resistant tuberculosis. Proc Natl Acad Sci USA 97:8180–8185.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section